Shield Therapeutics plc

AIM:STX 株式レポート

時価総額:UK£23.5m

Shield Therapeutics マネジメント

マネジメント 基準チェック /34

Shield Therapeutics' CEO is Anders Lundstrom, appointed in Jul 2024, has a tenure of less than a year. directly owns 0.001% of the company’s shares, worth £300.31. The average tenure of the management team and the board of directors is 1.6 years and 4 years respectively.

主要情報

Anders Lundstrom

最高経営責任者

US$53.5k

報酬総額

CEO給与比率n/a
CEO在任期間less than a year
CEOの所有権0.001%
経営陣の平均在職期間1.6yrs
取締役会の平均在任期間4yrs

経営陣の近況

Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now

Jun 13
Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now

Recent updates

Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Oct 30
Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt

Oct 12
Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt

Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story

Aug 01
Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story

Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now

Jun 13
Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now

Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost

May 22
Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost

Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation

Mar 02
Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation

What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates

May 06
What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates

Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain

Mar 15
Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain

We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow

Jan 27
We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow

Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares

Dec 15
Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares

CEO(最高経営責任者

Anders Lundstrom (62 yo)

less than a year

在職期間

US$53,542

報酬

Mr. Anders Lundstrom has been Interim Chief Executive Officer of Shield Therapeutics plc since July 24, 2024 and serves as its Independent Non-Executive Director since May 10, 2021. Mr. Lundstrom joined Or...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Anders Lundstrom
Interim CEO & Independent Non-Executive Directorless than a yearUS$53.54k0.0013%
£ 300.3
Christian Schweiger
Co-Founder & Non Executive Director16.8yrsUS$47.17k1.49%
£ 349.6k
Santosh Shanbhag
Chief Financial Officerless than a yearデータなしデータなし
Lucy Huntington-Bailey
General Counsel & Company Secretary7.2yrsデータなしデータなし
Suzanne Wood
Group HR Directorno dataデータなしデータなし
Carol Akinola
Head of Pharmacovigilance & Medical Informationno dataデータなしデータなし
Andrew Hurley
Chief Commercial Officer1.6yrsデータなしデータなし
Kate Armanetti
Senior Director of People & Cultureno dataデータなしデータなし

1.6yrs

平均在職期間

56.5yo

平均年齢

経験豊富な経営陣: STX's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


取締役

名称ポジション在職期間報酬所有権
Anders Lundstrom
Interim CEO & Independent Non-Executive Director3.5yrsUS$53.54k0.0013%
£ 300.3
Christian Schweiger
Co-Founder & Non Executive Director4.4yrsUS$47.17k1.49%
£ 349.6k
Hans Hasler
Independent Non Executive Chairman6.3yrsUS$119.83k0.70%
£ 165.0k
Rudolf Widmann
Non-Executive Directorless than a yearデータなしデータなし
Peter Llewellyn-Davies
Independent Non-Executive Director8.8yrsUS$76.49k0.023%
£ 5.3k
Christoph Gasche
Notable Scientific Advisory Boardno dataデータなしデータなし
Maria Lacerca-Allen
Independent Non-Executive Director3.5yrsUS$47.17k0.035%
£ 8.2k
Geoffrey Block
Notable Scientific Advisory Boardno dataデータなしデータなし
Michael Stockham
Notable Scientific Advisory Boardno dataデータなしデータなし
Jonathon Powell
Notable Scientific Advisory Boardno dataデータなしデータなし

4.0yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: STX's board of directors are considered experienced (4 years average tenure).